

1        **The SEK-1 p38 MAP kinase pathway modulates Gq signaling in *C. elegans***

2

3

4                    Jill M. Hoyt, Samuel K. Wilson, Madhuri Kasa, Jeremy S. Rise,

5                                    Irimi Topalidou, Michael Ailion

6

7                    Department of Biochemistry, University of Washington, Seattle, WA, 98195

8

9 Running Title: SEK-1 modulates Gq signaling

10

11

12 key words: p38 MAPK pathway, Gq signaling, animal behavior, *C. elegans*

13

14 Corresponding author:

15 Michael Ailion

16 Department of Biochemistry

17 University of Washington

18 Box 357350

19 1705 NE Pacific St

20 Seattle, WA 98195

21 Phone: 206-685-0111

22 email: [mailion@uw.edu](mailto:mailion@uw.edu)

23

24 **Abstract**

25 Gq is a heterotrimeric G protein that is widely expressed in neurons and  
26 regulates neuronal activity. To identify pathways regulating neuronal Gq signaling we  
27 performed a forward genetic screen in *Caenorhabditis elegans* for suppressors of  
28 activated Gq. One of the suppressors is an allele of *sek-1*, which encodes a mitogen-  
29 activated protein kinase kinase (MAPKK) in the p38 MAPK pathway. Here we show that  
30 *sek-1* mutants have a slow locomotion rate and that *sek-1* acts in acetylcholine neurons  
31 to modulate both locomotion rate and Gq signaling. Furthermore, we find that *sek-1* acts  
32 in mature neurons to modulate locomotion. Using genetic and behavioral approaches  
33 we demonstrate that other components of the p38 MAPK pathway also play a positive  
34 role in modulating locomotion and Gq signaling. Finally, we find that mutants in the  
35 SEK-1 p38 MAPK pathway partially suppress an activated mutant of the sodium leak  
36 channel NCA-1/NALCN, a downstream target of Gq signaling. Our results suggest that  
37 the SEK-1 p38 pathway may modulate the output of Gq signaling through NCA-1.

38

## 39 Introduction

40 Gq is a widely expressed heterotrimeric G protein that regulates a variety of  
41 biological processes ranging from neurotransmission to cardiovascular pathophysiology  
42 (Sánchez-Fernández *et al.* 2014). In the canonical Gq pathway, Gq activates  
43 phospholipase C $\beta$  (PLC $\beta$ ), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>)  
44 into the second messengers diacylglycerol (DAG) and inositol trisphosphate (IP<sub>3</sub>) (Rhee  
45 2001). In addition to PLC $\beta$ , other Gq effectors have been identified including kinases,  
46 such as protein kinase C $\zeta$  (PKC $\zeta$ ) and Bruton's tyrosine kinase (Btk) (Bence *et al.* 1997;  
47 García-Hoz *et al.* 2010; Vaqué *et al.* 2013), and guanine nucleotide exchange factors  
48 (GEFs) for the small GTPase Rho, such as Trio (Williams *et al.* 2007; Vaqué *et al.*  
49 2013). These noncanonical effectors bridge the activation of Gq to other cellular  
50 signaling cascades.

51 In order to study noncanonical pathways downstream of Gq, we used the nematode  
52 *C. elegans* which has a single Gqq homolog (EGL-30) and conservation of the other  
53 components of the Gq signaling pathway (Koelle 2016). In neurons, EGL-30 signals  
54 through EGL-8 (PLC $\beta$ ) (Lackner *et al.* 1999) and UNC-73 (ortholog of Trio RhoGEF)  
55 (Williams *et al.* 2007). UNC-73 activates RHO-1 (ortholog of RhoA), which has been  
56 shown to enhance neurotransmitter release through both diacylglycerol kinase (DGK-1)-  
57 dependent and DGK-1-independent pathways (McMullan *et al.* 2006).

58 To identify additional signaling pathways that modulate Gq signaling, we screened  
59 for suppressors of the activated Gq mutant *egl-30(tg26)* (Doi and Iwasaki 2002). *egl-*  
60 *30(tg26)* mutant animals exhibit hyperactive locomotion and a "loopy" posture in which  
61 worms have exaggerated, deep body bends and loop onto themselves (Bastiani *et al.*

62 2003; Topalidou *et al.* 2017). Here we identify one of the suppressors as a deletion  
63 allele in the gene *sek-1*. SEK-1 is a mitogen-activated protein kinase kinase (MAPKK),  
64 the *C. elegans* ortholog of mammalian MKK3/6 in the p38 MAPK pathway (Tanaka-Hino  
65 *et al.* 2002). The p38 MAPK pathway has been best characterized as a pathway  
66 activated by a variety of cellular stresses and inflammatory cytokines (Kyriakis and  
67 Avruch 2012). However, the p38 MAPK pathway has also been shown to be activated  
68 downstream of a G protein-coupled receptor in rat neurons (Huang *et al.* 2004). Btk, a  
69 member of the Tec family of tyrosine kinases, has been shown to act downstream of Gq  
70 to activate the p38 MAPK pathway (Bence *et al.* 1997), but *C. elegans* lacks Btk and  
71 other Tec family members (Plowman *et al.* 1999).

72 SEK-1 is activated by the MAPKKK NSY-1 (ortholog of ASK1) and activates the p38  
73 MAPKs PMK-1 and PMK-2 (Andrusiak and Jin 2016). The p38 MAPK pathway  
74 consisting of NSY-1, SEK-1, and PMK-1 is required for innate immunity in *C. elegans*  
75 (Kim *et al.* 2002). NSY-1 and SEK-1 are also required for the specification of the  
76 asymmetric AWC olfactory neurons (Sagasti *et al.* 2001; Tanaka-Hino *et al.* 2002); the  
77 p38 orthologs PMK-1 and PMK-2 function redundantly in AWC specification (Pagano *et*  
78 *al.* 2015). For both innate immunity and AWC specification, the p38 MAPK pathway acts  
79 downstream of the adaptor protein TIR-1 (an ortholog of SARM) (Couillault *et al.* 2004;  
80 Chuang and Bargmann 2005). Here we show that the pathway consisting of TIR-1,  
81 NSY-1, SEK-1, PMK-1 and PMK-2 also acts to modulate locomotion downstream of Gq  
82 signaling.

83

84 **Materials and Methods**

## 85 **C. elegans strains and maintenance**

86 All strains were cultured using standard methods and maintained at 20°C  
87 (Brenner 1974). The *sek-1(yak42)* mutant was isolated from an ENU mutagenesis  
88 suppressor screen of the activated Gq mutant *egl-30(tg26)* (Ailion *et al.* 2014). *sek-*  
89 *1(yak42)* was outcrossed away from *egl-30(tg26)* before further analysis. Double mutant  
90 strains were constructed using standard methods (Fay 2006), often with linked  
91 fluorescent markers (Frokjaer-Jensen *et al.* 2014) to balance mutations with subtle  
92 visible phenotypes. Table S1 contains all the strains used in this study.

93

### 94 **Mapping**

95 *yak42* was mapped using its slow locomotion phenotype and its *egl-30(tg26)*  
96 suppression phenotype. *yak42* was initially mapped to the X chromosome using strains  
97 EG1000 and EG1020, which carry visible marker mutations. These experiments  
98 showed that *yak42* was linked to *lon-2*, but at least several map units away. *yak42* was  
99 further mapped to about one map unit (m.u.) away from the red fluorescent insertion  
100 marker *oxTi668* which is located at +0.19 m.u. on the X chromosome.

101

### 102 **Whole-genome sequencing**

103 Strain XZ1233 *egl-30(tg26); yak42* was used for whole-genome sequencing to  
104 identify candidate *yak42* mutations. XZ1233 was constructed by crossing a 2X  
105 outcrossed *yak42* strain back to *egl-30(tg26)*. Thus, in XZ1233, *yak42* has been  
106 outcrossed 3X from its original isolate. DNA was isolated from XZ1233 and purified  
107 according to the Hobert Lab protocol (<http://hobertlab.org/whole-genome-sequencing/>).

108 Ion Torrent sequencing was performed at the University of Utah DNA Sequencing Core  
109 Facility. The resulting data contained 10,063,209 reads of a mean read length of 144  
110 bases, resulting in about 14X average coverage of the *C. elegans* genome. The  
111 sequencing data were uploaded to the Galaxy web platform and we used the public  
112 server at usegalaxy.org to analyze the data (Afgan *et al.* 2016). We identified and  
113 annotated variants with the Unified Genotyper and SnpEff tools, respectively (DePristo  
114 *et al.* 2011; Cingolani *et al.* 2012). We filtered out variants found in other strains we  
115 sequenced, leaving us with 605 homozygous mutations. The X chromosome contained  
116 94 mutations: 55 SNPs and 39 indels. Of these, four SNPs were non-synonymous  
117 mutations in protein-coding genes, but only two were within 5 m.u. of *oxTi668*. However,  
118 we were unable to identify *yak42* from the candidate polymorphisms located near  
119 *oxTi668*. Transgenic expression of the most promising candidate *pcyt-1* did not rescue  
120 *yak42*. Instead, to identify possible deletions, we scrolled through 2 MB of aligned reads  
121 on the UCSC Genome Browser starting at -4.38 m.u. and moving towards the middle of  
122 the chromosome (0 m.u.), looking for regions that lacked sequence coverage. We found  
123 a 3713 bp deletion that was subsequently confirmed to be the *yak42* causal mutation,  
124 affecting the gene *sek-1* located at -1.14 m.u.

125

## 126 **Locomotion assays**

127 Locomotion assay plates were made by seeding 10 cm nematode growth  
128 medium plates with 150  $\mu$ l of an *E. coli* OP50 stock culture, spread with sterile glass  
129 beads to cover the entire plate. Bacterial lawns were grown at room temperature  
130 (22.5°C -24.5°C) for 24 hrs and then stored at 4°C until needed. All locomotion assays

131 were performed on first-day adults at room temperature (22.5°C -24.5°C). L4 stage  
132 larvae were picked the day before the assay and the experimenter was blind to the  
133 genotypes of the strains assayed. For experiments on strains carrying  
134 extrachromosomal arrays, the *sek-1(km4)* control worms were animals from the same  
135 plate that had lost the array.

136         Body bend assays were performed as described (Miller *et al.* 1999). A single  
137 animal was picked to the assay plate, the plate lid was returned, and the animal allowed  
138 to recover for 30 s. Body bends were then counted for one minute, counting each time  
139 the worm's tail reached the minimum or maximum amplitude of the sine wave. All  
140 strains in an experiment were assayed on the same assay plate. For experiments with  
141 *egl-8*, *unc-73*, and *rund-1* mutants, worms were allowed a minimal recovery period (until  
142 the worms started moving forward, 5 sec maximum) prior to counting body bends.

143         For the heat shock experiment, plates of first-day adults were parafilmmed and  
144 heat-shocked in a 34°C water bath for 1 hr. Plates were then un-parafilmmed and  
145 incubated at 20°C for five hours before performing body bend assays.

146         Radial locomotion assays were performed by picking animals to the middle of an  
147 assay plate. Assay plates were incubated at 20°C for 20 hr and the distances of the  
148 worms from the starting point were measured.

149         Quantitative analysis of the waveform of worm tracks was performed as  
150 described (Topalidou *et al.* 2017). Briefly, worm tracks were photographed and Image J  
151 was used to measure the period and amplitude. The value for each animal was the  
152 average of five period/amplitude ratios.

153



154 ***C. elegans pictures***

155 Pictures of worms were taken at 60X on a Nikon SMZ18 microscope with the DS-  
156 L3 camera control system. The worms were age-matched as first-day adults and each  
157 experiment set was photographed on the same locomotion assay plate prepared as  
158 described above. The images were processed using ImageJ and were rotated, cropped,  
159 and converted to grayscale.

160

161 ***Molecular biology***

162 Plasmids were constructed using the Gateway cloning system (Invitrogen).  
163 Plasmids and primers used are found in Table S2. The *sek-1* cDNA was amplified by  
164 RT-PCR from worm RNA and cloned into a Gateway entry vector. To ensure proper  
165 expression of *sek-1*, an operon GFP was included in expression constructs with the  
166 following template: (promoter)p::*sek-1*(cDNA)::*tbb-2utr*::*gpd-2 operon*::GFP::*H2B:cye-*  
167 *1utr* (Frøkjær-Jensen *et al.* 2012). This resulted in untagged SEK-1, but expression  
168 could be monitored by GFP expression.

169

170 ***Injections***

171 *C. elegans* strains with extrachromosomal arrays were generated by standard  
172 methods (Mello *et al.* 1991). Injection mixes were made with a final total concentration  
173 of 100 ng/μL DNA. Constructs were injected at 5 ng/μL, injection markers at 5 ng/μL,  
174 and the carrier DNA Litmus 38i at 90 ng/μL. Multiple lines of animals carrying  
175 extrachromosomal arrays were isolated and had similar behaviors as observed by eye.  
176 The line with the highest transmittance of the array was assayed.

177

## 178 **Statistical analysis**

179 At the beginning of the project, a power study was conducted on pilot body bend  
180 assays using wild type and *sek-1(yak42)* worms. To achieve a power of 0.95, it was  
181 calculated that 17 animals should be assayed per experiment. Data were analyzed to  
182 check if normally distributed (using the D'Agostino-Pearson and Shapiro-Wilk normality  
183 tests) and then subjected to the appropriate analysis using GraphPad Prism 5. For data  
184 sets with three or more groups, if the data were normal they were analyzed with a one-  
185 way ANOVA; if not, with a Kruskal-Wallis test. Post-hoc tests were used to compare  
186 data sets within an experiment. Reported p-values are corrected. Table S3 contains the  
187 statistical tests for each experiment.  $p < 0.05 = *$ ;  $p < 0.01 = **$ ;  $p < 0.001 = ***$ .

188

## 189 **Reagent and Data Availability**

190 Strains and plasmids are shown in Table S1 and Table S2 and are available from  
191 the *Caenorhabditis* Genetics Center (CGC) or upon request. The authors state that all  
192 data necessary for confirming the conclusions presented in the article are represented  
193 fully within the article and Supplemental Material.

194

## 195 **Results**

### 196 ***sek-1* suppresses activated Gq**

197 To identify genes acting downstream of Gαq, we performed a forward genetic  
198 screen for suppressors of the activated Gq mutant, *egl-30(tg26)* (Doi and Iwasaki 2002).  
199 *egl-30(tg26)* worms are hyperactive and have a “loopy” posture characterized by an

200 exaggerated waveform (Figure 1B-1E). Thus, we screened for worms that are less  
201 hyperactive and less loopy. We isolated a recessive suppressor, *yak42*, and mapped it  
202 to the middle of the X chromosome (see Materials and Methods). Whole-genome  
203 sequencing revealed that *yak42* carries a large deletion of the *sek-1* gene from  
204 upstream of the start codon into exon 4 (Figure 1A). *yak42* also failed to complement  
205 *sek-1(km4)*, a previously published *sek-1* deletion allele, for the Gq suppression  
206 phenotype (Figure 1A) (Tanaka-Hino *et al.* 2002).

207 *egl-30(tg26)* double mutants with either *sek-1(yak42)* or *sek-1(km4)* are not loopy  
208 (Figure 1B-1D) and are not hyperactive (Figure 1E and S1A). *sek-1(yak42)* was  
209 outcrossed from *egl-30(tg26)* and assayed for locomotion defects. Both the *sek-*  
210 *1(yak42)* and *sek-1(km4)* mutants are coordinated but move more slowly than wild-type  
211 (Figure 1F). The *sek-1(ag1)* point mutation (Kim *et al.* 2002) also causes a similar slow  
212 locomotion phenotype (Figure S1B). To test whether the *egl-30(tg26)* suppression  
213 phenotype might be an indirect effect of the slow locomotion of a *sek-1* mutant, we built  
214 an *egl-30(tg26)* double mutant with a mutation in *unc-82*, a gene required for normal  
215 muscle structure. *unc-82* mutants are coordinated but move slowly, similar to a *sek-1*  
216 mutant (Hoppe *et al.* 2010). However, although an *egl-30(tg26) unc-82(e1220)* double  
217 mutant moves more slowly than *egl-30(tg26)* (Figure S1C), it is still loopy (Figure 1B-  
218 1D). Thus, *sek-1* appears to be a specific suppressor of activated *egl-30*.

219 The *egl-30(tg26)* allele causes an R243Q missense mutation in the G $\alpha$  switch III  
220 region that has been shown to reduce both the intrinsic GTPase activity of the G protein  
221 and render it insensitive to GTPase-activation by a regulator of G protein signaling  
222 (RGS) protein, thus leading to increased G protein activation (Natochin and Artemyev

223 2003). To test whether the suppression of *egl-30(tg26)* by *sek-1* is specific for this *egl-*  
224 *30* allele, we built a double mutant between *sek-1(km4)* and the weaker activating  
225 mutation *egl30(js126)*. *egl-30(js126)* causes a V180M missense mutation in the G $\alpha$   
226 switch I region immediately adjacent to one of the key residues required for GTPase  
227 catalysis (Hawasli *et al.* 2004). Thus, the *tg26* and *js126* alleles activate EGL-30  
228 through different mechanisms. The *sek-1(km4)* mutant also suppresses the  
229 hyperactivity and loopy waveform of *egl-30(js126)* (Figure 1G, 1H), demonstrating that  
230 *sek-1* suppression of activated *egl-30* is not allele-specific.

231 EGL-30/G $\alpha$ q is negatively regulated by GOA-1, the worm Gao/i ortholog, and the  
232 RGS protein EAT-16 (Hajdu-Cronin *et al.* 1999). We tested whether *sek-1* also  
233 suppresses the *goa-1* and *eat-16* loss-of-function mutants that cause a hyperactive and  
234 loopy phenotype similar to activated *egl-30* mutants. *sek-1(km4)* suppresses the  
235 hyperactivity and loopy waveform of *goa-1(sa734)* (Figure S1D, S1E). However, though  
236 *sek-1(km4)* suppresses the hyperactivity of *eat-16(tm775)*, it did not significantly  
237 suppress the loopy waveform (Figure S1F, S1G). One possible downstream effector of  
238 GOA-1 is the DAG kinase DGK-1 that inhibits DAG-dependent functions such as  
239 synaptic vesicle release (Nurrish *et al.* 1999; Miller *et al.* 1999). *dgk-1(sy428)* animals  
240 are hyperactive, but the *sek-1 dgk-1* double mutant is uncoordinated and looks like  
241 neither *sek-1* nor *dgk-1* mutants, confounding the interpretation of how *sek-1* genetically  
242 interacts with *dgk-1*.

243

244 ***sek-1* acts in mature acetylcholine neurons**

245 *egl-30* is widely expressed and acts in neurons to modulate locomotion (Lackner  
246 *et al.* 1999), so it is possible that *sek-1* also acts in neurons to modulate Gq signaling.  
247 *sek-1* is expressed in neurons, intestine, and several other tissues (Tanaka-Hino *et al.*  
248 2002) and has been shown to function in GABA neurons to promote synaptic  
249 transmission (Vashlishan *et al.* 2008).

250 To identify the cell type responsible for the *sek-1* locomotion phenotypes, we  
251 expressed the wild-type *sek-1* cDNA under different cell-specific promoters and tested  
252 for transgenic rescue of a *sek-1* null mutant. Expression of *sek-1* in all neurons (using  
253 the *unc-119* promoter) or in acetylcholine neurons (*unc-17* promoter) was sufficient to  
254 rescue the *sek-1* mutant slow locomotion phenotype, but expression in GABA neurons  
255 (*unc-47* promoter) was not sufficient to rescue (Figure 2A, B). These results indicate  
256 that *sek-1* acts in acetylcholine neurons to modulate locomotion rate.

257 We next tested whether *sek-1* acts in neurons to suppress *egl-30(tg26)*.  
258 Expression of *sek-1* under pan-neuronal and acetylcholine neuron promoters reversed  
259 the *sek-1* suppression of *egl-30(tg26)*. Specifically, *egl-30(tg26) sek-1* double mutants  
260 expressing wild-type *sek-1* in all neurons or acetylcholine neurons resembled the *egl-*  
261 *30(tg26)* single mutant (Figure 2C-E). However, expression of *sek-1* in GABA neurons  
262 did not reverse the suppression phenotype (Figure 2C-E). Together, these data show  
263 that *sek-1* acts in acetylcholine and not GABA neurons to modulate both wild-type  
264 locomotion rate and to modulate Gq signaling.

265 To narrow down the site of *sek-1* action, we expressed *sek-1* in head (*unc-17H*  
266 promoter) and motorneuron (*unc-17 $\beta$*  promoter) acetylcholine neuron subclasses  
267 (Topalidou *et al.* 2017). Expression of *sek-1* in acetylcholine motorneurons rescued the

268 *sek-1* slow locomotion phenotype (Figure S2A), suggesting that the slow locomotion of  
269 *sek-1* mutants is due to a loss of *sek-1* in acetylcholine motorneurons. However,  
270 expression of *sek-1* in either the head acetylcholine neurons or motorneurons partially  
271 reversed the *sek-1* suppression of *egl-30(tg26)* hyperactivity (Figure S2B), suggesting  
272 that the hyperactivity of activated Gq mutants may result from excessive Gq signaling in  
273 both head acetylcholine neurons and acetylcholine motorneurons; *sek-1* may act in Gq  
274 signaling in both neuronal cell types. By contrast, expression of *sek-1* in head  
275 acetylcholine neurons but not motorneurons reversed the *sek-1* suppression of the *egl-*  
276 *30(tg26)* loopy waveform (Figure S2C), suggesting that the loopy posture of activated  
277 Gq mutants may result from excessive Gq signaling in head acetylcholine neurons, and  
278 *sek-1* may act in those neurons to control body posture.

279         Because *sek-1* acts in the development of the AWC asymmetric neurons, we  
280 asked whether *sek-1* also has a developmental role in modulating locomotion by testing  
281 whether adult-specific *sek-1* expression (driven by a heat-shock promoter) is sufficient  
282 to rescue the *sek-1* mutant. We found that *sek-1* expression in adults rescues the *sek-1*  
283 slow locomotion phenotype (Figure 2F). This result indicates that *sek-1* is not required  
284 for development of the locomotion circuit and instead acts in mature neurons to  
285 modulate locomotion.

286

### 287 **The p38 MAPK pathway is a positive regulator of Gq signaling**

288         SEK-1 is the MAPKK in the p38 MAPK pathway consisting of the adaptor protein  
289 TIR-1, NSY-1 (MAPKKK), SEK-1 (MAPKK), and PMK-1 or PMK-2 (MAPKs) (Tanaka-  
290 Hino *et al.* 2002; Andrusiak and Jin 2016). We tested whether the entire p38 MAPK

291 signaling module also modulates locomotion rate and suppression of activated Gq. Both  
292 *tir-1(tm3036)* and *nsy-1(ok593)* mutant animals have slow locomotion on their own and  
293 also suppress the hyperactivity and loopy waveform of *egl-30(tg26)* (Figure 3A-D, G and  
294 H). We also tested single mutants in each of the three worm p38 MAPK genes (*pmk-1*,  
295 *pmk-2* and *pmk-3*) and a *pmk-2 pmk-1* double mutant. Although we found that the *pmk-*  
296 *2* and *pmk-3* single mutants were slightly slow on their own, only the *pmk-2 pmk-1*  
297 double mutant phenocopied *sek-1* and suppressed both the hyperactivity and loopy  
298 waveform of *egl-30(tg26)* (Figure 3E-H). Thus, *pmk-2* and *pmk-1* act redundantly  
299 downstream of *sek-1* to suppress *egl-30(tg26)*. These data suggest that the p38 MAPK  
300 pathway modulates locomotion rate in *C. elegans* and acts genetically downstream of  
301 *egl-30*.

302         The JNK MAPK pathway, related to the p38 MAPK family, also modulates  
303 locomotion in *C. elegans*. Specifically, the JNK pathway members *jkk-1* (JNK MAPKK)  
304 and *jnk-1* (JNK MAPK) have been shown to act in GABA neurons to modulate  
305 locomotion (Kawasaki 1999). We found that the *jkk-1* and *jnk-1* single mutants had slow  
306 locomotion and that the double mutants with p38 MAPK pathway members exhibited an  
307 additive slow locomotion phenotype (Figure S3A). Moreover, neither *jkk-1* nor *jnk-1*  
308 suppressed the loopy phenotype of *egl-30(tg26)* (Figure S3B). Thus, the JNK and p38  
309 MAPK pathways modulate locomotion independently and the JNK pathway is not  
310 involved in Gq signaling.

311         We also tested the involvement of possible p38 MAPK pathway effectors. One of  
312 the targets of PMK-1 is the transcription factor ATF-7 (Shivers *et al.* 2010). Both the *atf-*  
313 *7(qd22 qd130)* loss-of-function mutant and the *atf-7(qd22)* gain-of-function mutant

314 moved slowly compared to wild-type animals (Figure S3C). However, *atf-7(qd22 qd130)*  
315 did not suppress the loopiness of *egl-30(tg26)* (Figure S3B), suggesting that *atf-7* is not  
316 a target of this pathway, or else it acts redundantly with other downstream p38 MAPK  
317 targets. We also tested *gap-2*, the closest *C. elegans* homolog of ASK1-interacting  
318 Protein (AIP1) which activates ASK1 (the ortholog of *C. elegans* NSY-1) in mammalian  
319 systems (Zhang *et al.* 2003). A *C. elegans gap-2* mutant has no locomotion defect  
320 (Figure S3D). Finally, we tested VHP-1, a phosphatase for p38 and JNK MAPKs that  
321 inhibits p38 MAPK signaling (Kim *et al.* 2004). However, the *vhp-1(sa366)* mutant also  
322 has no locomotion defect (Figure S3D).

323 *egl-30(tg26)* animals are loopy and hyperactive so we tested whether increased  
324 activation of the TIR-1/p38 MAPK signaling module causes similar phenotypes. The *tir-*  
325 *1(ky648tg26)* allele leads to a gain-of-function phenotype in the AWC neuron  
326 specification (Chang *et al.* 2011), but does not cause loopy or hyperactive locomotion  
327 (Figure S3E, F).

328

### 329 **Genetic interactions of *sek-1* with pathways acting downstream of Gq**

330 Our forward genetic screen for suppressors of *egl-30(tg26)* identified mutants  
331 that fall into three different categories: mutants in the canonical Gq pathway such as the  
332 PLC *egl-8* ((Lackner *et al.* 1999), mutants in the RhoGEF Trio pathway such as *unc-73*  
333 (Williams *et al.*, 2007), and mutants that affect dense-core vesicle biogenesis and  
334 release (Ailion *et al.* 2014; Topalidou *et al.* 2016).

335 To test if *sek-1* acts in any of these pathways we built double mutants between  
336 *sek-1* and members of each pathway. Loss-of-function alleles of *egl-8(sa47)*, *unc-*



337 *73(ox317)*, and *rund-1(tm3622)* have slow locomotion (Figure 4A-C). We found that  
338 *sek-1* enhances the slow locomotion phenotype of *egl-8* and *rund-1* single mutants,  
339 suggesting that *sek-1* does not act in the same pathway as *egl-8* or *rund-1* (Figure 4A,  
340 B). By contrast, *sek-1* does not enhance the slow locomotion phenotype of *unc-73*  
341 mutants (Figure 4C), suggesting that *sek-1* may act in the same genetic pathway as the  
342 Trio RhoGEF *unc-73*.

343 We next tested whether *sek-1* interacts with *rho-1*, encoding the small G protein  
344 Rho that is activated by Trio. Because *rho-1* is required for viability (Jantsch-Plunger *et*  
345 *al.* 2000), we used an integrated transgene overexpressing an activated *rho-1* mutant  
346 allele specifically in acetylcholine neurons. Animals carrying this activated RHO-1  
347 transgene, referred to here as *rho-1(gf)*, have a loopy posture reminiscent of *egl-*  
348 *30(tg26)* (McMullan *et al.* 2006), and a decreased locomotion rate (Figure 4D-F). *rho-*  
349 *1(gf) sek-1(km4)* double mutants had a loopy body posture like *rho-1(gf)* and an even  
350 slower locomotion rate (Figure 4D-F), suggesting that *sek-1* and *rho-1(gf)* mutants have  
351 additive locomotion phenotypes. However, both *sek-1(km4)* and *sek-1(yak42)* weakly  
352 suppress the slow growth rate of the *rho-1(gf)* mutant (data not shown). Because *sek-1*  
353 does not enhance *unc-73* mutants and suppresses some aspects of the *rho-1(gf)*  
354 mutant, *sek-1* may modulate output of the Rho pathway, though it probably is not a  
355 direct transducer of Rho signaling.

356

### 357 ***sek-1* and *nsy-1* partially suppress activated NCA**

358 To clarify the relationship of the SEK-1 p38 MAPK pathway to the Rho pathway  
359 acting downstream of Gq, we examined interactions with *nca-1*, a downstream target of

360 the Gq-Rho pathway (Topalidou *et al.* 2017). NCA-1 and its orthologs are sodium leak  
361 channels associated with rhythmic behaviors in several organisms (Nash *et al.* 2002; Lu  
362 *et al.* 2007; Shi *et al.* 2016). In *C. elegans*, NCA-1 potentiates persistent motor circuit  
363 activity and sustains locomotion (Gao *et al.* 2015).

364 We tested whether *sek-1* and *nsy-1* mutants suppress the activated NCA-1  
365 mutant *ox352*, referred to as *nca-1(gf)*. The *nca-1(gf)* animals are coiled and  
366 uncoordinated; thus, it is difficult to measure their locomotion rate by the body bend  
367 assay because they do not reliably propagate sinusoidal waves down the entire length  
368 of their body. Instead, we used a radial locomotion assay in which we measured the  
369 distance animals moved from the center of a plate. *nca-1(gf)* double mutants with either  
370 *sek-1(km4)* or *nsy-1(ok593)* uncoil a bit but still exhibit uncoordinated locomotion  
371 (Figure 5A). In fact, though these double mutants show more movement in the anterior  
372 half of their bodies than *nca-1(gf)*, they propagate body waves to their posterior half  
373 even more poorly than the *nca-1(gf)* mutant. However, both *sek-1* and *nsy-1* partially  
374 suppress the loopy waveform of the *nca-1(gf)* mutant (Figure 5A, B) and in radial  
375 locomotion assays, *sek-1* and *nsy-1* weakly suppressed the *nca-1(gf)* locomotion defect  
376 (Figure 5C). Additionally, both *sek-1* and *nsy-1* partially suppress the small body size of  
377 *nca-1(gf)* (Figure S4A). Together these data suggest that mutations in the SEK-1 p38  
378 MAPK pathway suppress some aspects of the *nca-1(gf)* mutant.

379 Given that *sek-1* acts in acetylcholine neurons to modulate wild-type and *egl-*  
380 *30(tg26)* locomotion, we tested whether *sek-1* also acts in these neurons to suppress  
381 *nca-1(gf)*. Expression of *sek-1* in all neurons or in acetylcholine neurons of *nca-1(gf)*  
382 *sek-1(km4)* animals restored the *nca-1(gf)* loopy phenotype (Figure 5D, E). By contrast,

383 expression of *sek-1* in GABA neurons did not affect the loopy posture of the *nca-1(gf)*  
384 *sek-1* double mutant (Figure 5D, E). These data suggest that *sek-1* acts in acetylcholine  
385 neurons to modulate the body posture of *nca-1(gf)* as well. However, in radial  
386 locomotion assays, expression of *sek-1* in none of these neuron classes significantly  
387 altered the movement of the *nca-1(gf) sek-1* double mutant (Figure S4B), though the  
388 weak suppression of *nca-1(gf)* by *sek-1* in this assay makes it difficult to interpret these  
389 negative results. To further narrow down the site of action of *sek-1* for its NCA  
390 suppression phenotypes, we expressed it in subclasses of acetylcholine neurons.  
391 Surprisingly, expression of *sek-1* in acetylcholine motoneurons but not head  
392 acetylcholine neurons was sufficient to restore the loopy posture of the *nca-1(gf)* mutant  
393 (Figure 5E), the opposite of what we found for *sek-1* modulation of the loopy posture of  
394 the activated Gq mutant, suggesting that the loopy posture of *nca-1(gf)* mutants may  
395 result from excessive NCA-1 activity in acetylcholine motoneurons. Additionally,  
396 expression of *sek-1* in either the head acetylcholine neurons or the motoneurons  
397 restored the *nca-1(gf)* small body size phenotype (Figure S4C). We make the tentative  
398 conclusion that *sek-1* acts in acetylcholine neurons to modulate *nca-1(gf)* body posture  
399 and size, but we were not able to conclusively narrow down its site of action further,  
400 possibly due to the uncoordinated phenotype of *nca-1(gf)* and the weaker suppression  
401 of *nca-1(gf)* by *sek-1* .

402

## 403 **Discussion**

404 The p38 MAPK pathway has been best characterized as a pathway activated by  
405 a variety of cellular stresses and inflammatory cytokines (Kyriakis and Avruch 2012), but

406 it has also been implicated in neuronal function, including some forms of mammalian  
407 synaptic plasticity (Bolshakov *et al.* 2000; Rush *et al.* 2002; Huang *et al.* 2004). In this  
408 study we identified a new neuronal role for the mitogen-activated protein kinase kinase  
409 SEK-1 and the p38 MAPK pathway as a positive modulator of locomotion rate and Gq  
410 signaling. The physiological importance of this pathway is clear under conditions of  
411 elevated Gq signaling but is less obvious during normal wild-type locomotion, consistent  
412 with the observation that *sek-1* mutations have a relatively weak effect on synaptic  
413 transmission in a wild-type background (Vashlishan *et al.* 2008). Thus, the SEK-1 p38  
414 MAPK pathway may be more important for modulation of Gq signaling and synaptic  
415 strength than for synaptic transmission per se.

416 In addition to SEK-1, we identified other p38 pathway components that modulate  
417 Gq signaling. Specifically, we found that *tir-1*, *nsy-1* and *pmk-1 pmk-2* mutants exhibit  
418 locomotion defects identical to *sek-1* and suppress activated Gq, suggesting that they  
419 act in a single p38 pathway to modulate signaling downstream of Gq. These results  
420 indicate a redundant function for PMK-1 and PMK-2 in modulating locomotion rate and  
421 Gq signaling. PMK-1 and PMK-2 also act redundantly for some other neuronal roles of  
422 the p38 pathway, such as the development of the asymmetric AWC neurons and to  
423 regulate induction of serotonin biosynthesis in the ADF neurons in response to  
424 pathogenic bacteria (Shivers *et al.* 2009; Pagano *et al.* 2015). By contrast, PMK-1 acts  
425 alone in the intestine to regulate innate immunity and in interneurons to regulate  
426 trafficking of the GLR-1 glutamate receptor (Pagano *et al.* 2015; Park and Rongo 2016).

427 What are the downstream effectors of the SEK-1 p38 MAPK pathway that  
428 modulates locomotion? There are several known downstream effectors of p38 MAPK

429 signaling in *C. elegans*, including the transcription factor ATF-7 (Shivers *et al.* 2010).  
430 Our data indicate that ATF-7 is not required for the p38 MAPK-dependent modulation of  
431 Gq signaling. The p38 MAPK pathway may activate molecules other than transcription  
432 factors or may activate multiple downstream effectors.

433         How does the SEK-1 p38 pathway modulate the output of Gq signaling? One of  
434 the pathways that transduces signals from Gq includes the RhoGEF Trio/UNC-73, the  
435 small GTPase Rho, and the cation channel NALCN/NCA-1 (Williams *et al.* 2007;  
436 Topalidou *et al.* 2017). Compared to other pathways downstream of Gq, mutants in the  
437 Rho-Nca pathway are particularly strong suppressors of the loopy waveform phenotype  
438 of the activated Gq mutant (Topalidou *et al.* 2017). Similarly, we found that mutations in  
439 the SEK-1 p38 MAPK pathway strongly suppress the loopy waveform of the activated  
440 Gq mutant, suggesting that the SEK-1 pathway might modulate Gq signal output  
441 through the Rho-Nca branch. Consistent with this, we found that mutations in the SEK-1  
442 p38 MAPK pathway partially suppress an activated NCA-1 mutant. Given the  
443 precedence for direct phosphorylation of sodium channels by p38 to regulate channel  
444 properties (Wittmack *et al.* 2005; Hudmon *et al.* 2008), it is possible that PMK-1 and  
445 PMK-2 phosphorylate NCA-1 to regulate its expression, localization, or activity.

446         Consistent with the observation that Gq acts in acetylcholine neurons to stimulate  
447 synaptic transmission (Lackner *et al.* 1999), we found that *sek-1* acts in acetylcholine  
448 neurons to modulate the locomotion rate in both wild-type and activated Gq mutants.  
449 *sek-1* also acts in acetylcholine neurons to modulate the loopy waveform of both  
450 activated Gq and activated *nca-1* mutants, and the size of activated *nca-1* mutants.  
451 However, our data attempting to narrow down the site of action of *sek-1* suggest that it

452 may act in both head acetylcholine neurons and acetylcholine motoneurons, and that  
453 the waveform is probably controlled by at least partially distinct neurons from those that  
454 control locomotion rate. Further work will be required to identify the specific neurons  
455 where Gq, NCA-1 and the SEK-1 pathway act to modulate locomotion rate and  
456 waveform, and determine whether they all act together in the same cell.

457

## 458 **Acknowledgements**

459 We thank Dennis Kim and Chiou-Fen Chuang for strains, Pin-An Chen and Erik  
460 Jorgensen for the *nca-1(gf)* mutant *ox352*, Chris Johnson for the fine mapping of *yak42*,  
461 Jordan Hoyt for help with Galaxy to analyze WGS data, and Dana Miller for providing  
462 access to her microscope camera. Some strains were provided by the CGC, which is  
463 funded by NIH Office of Research Infrastructure Programs (P40 OD010440). J.M.H was  
464 supported in part by Public Health Service, National Research Service Award  
465 T32GM007270, from the National Institute of General Medical Sciences. M.A. is an  
466 Ellison Medical Foundation New Scholar. This work was supported by NIH grant R00  
467 MH082109 to M.A.

468

## 469 **Figure Legends**

### 470 **Figure 1. *sek-1* acts downstream of Gq to modulate locomotion behavior**

471 (A) Gene structure of *sek-1*. White boxes depict the 5' and 3' untranslated regions,  
472 black boxes depict exons, and lines show introns. The positions of the *yak42* and *km4*  
473 deletions are shown. *yak42* is a 3713 bp deletion that extends to 1926 bp upstream of

474 the start codon. Drawn with Exon-Intron Graphic Maker  
475 (<http://www.wormweb.org/exonintron>). Scale bar is 100 bp.  
476 (B-D) *sek-1(yak42)* and *sek-1(km4)* suppress the loopy waveform of the activated Gq  
477 mutant *egl-30(tg26)*. *unc-82(e1220)* does not suppress *egl-30(tg26)*. (B) Photos of first-  
478 day adult worms. WT: wild type. (C) Quantification of the waveform phenotype. \*\*\*,  
479  $p < 0.001$ ; ns,  $p > 0.05$  compared to *egl-30(tg26)*. Error bars = SEM,  $n = 5$ . (D) Photos of  
480 worm tracks.  
481 (E) The activated Gq mutant *egl-30(tg26)* is hyperactive and is suppressed by *sek-*  
482 *1(yak42)* and *sek-1(km4)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .  
483 (F) *sek-1* mutant worms have slow locomotion. \*\*\*,  $p < 0.001$  compared to wild-type.  
484 Error bars = SEM,  $n = 20$ .  
485 (G) *sek-1(km4)* suppresses the hyperactive locomotion of the activated Gq mutant *egl-*  
486 *30(js126)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .  
487 (H) *sek-1(km4)* suppresses the loopy waveform of the activated Gq mutant *egl-*  
488 *30(js126)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 5$ .

489

490 **Figure 2. *sek-1* acts in mature acetylcholine neurons to modulate locomotion**

491 (A) *sek-1* acts in neurons to modulate locomotion rate. The *sek-1* wild-type cDNA driven  
492 by the *unc-119* pan-neuronal promoter [*unc-119p::sek-1(+)*] rescues the slow  
493 locomotion phenotype of *sek-1(km4)* worms. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .  
494 (B) *sek-1* acts in acetylcholine neurons to modulate locomotion rate. *sek-1* WT cDNA  
495 driven by the *unc-17* acetylcholine neuron promoter [*unc-17p::sek-1(+)*] rescues the  
496 slow locomotion phenotype of *sek-1(km4)* worms but *sek-1* expression in GABA

497 neurons using the *unc-47* promoter [*unc-47p::sek-1(+)*] does not. \*\*\*,  $p < 0.001$ , error  
498 bars = SEM,  $n=20$ .

499 (C-D) *sek-1* acts in acetylcholine neurons to modulate the loopy waveform of *egl-*

500 *30(tg26)*. *egl-30(tg26) sek-1(km4)* worms expressing *unc-119p::sek-1(+)* or *unc-*

501 *17p::sek-1(+)* are loopy like *egl-30(tg26)*, but *egl-30(tg26) sek-1(km4)* worms expressing

502 *unc-47p::sek-1(+)* are similar to *egl-30(tg26) sek-1*. (C) Photos of worms. (D)

503 Quantification of waveform phenotype. \*\*\*,  $p < 0.001$ ; ns,  $p > 0.05$ . Error bars = SEM,  $n=5$ .

504 (E) *sek-1* acts in acetylcholine neurons to modulate the locomotion rate of *egl-30(tg26)*.

505 *egl-30(tg26) sek-1(km4)* worms expressing *unc-119p::sek-1(+)* or *unc-17p::sek-1(+)*

506 have an increased locomotion rate compared to *egl-30(tg26) sek-1*, but *egl-30(tg26)*

507 *sek-1(km4)* worms expressing *unc-47p::sek-1(+)* are similar to *egl-30(tg26) sek-1*. \*\*\*,

508  $p < 0.001$ , \*\*,  $p < 0.01$ ; ns,  $p > 0.05$ . Error bars = SEM,  $n=17-20$ .

509 (F) *sek-1* acts in mature neurons to modulate locomotion rate. Heat-shock induced

510 expression of *sek-1* in adults (*hsp-16.2p::sek-1(+)*) rescues the slow locomotion

511 phenotype of *sek-1(km4)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n=20$ .

512

513 **Figure 3. The p38 MAPK pathway modulates locomotion downstream of *egl-30***

514 (A) *tir-1(tm3036)* mutant animals have slow locomotion. \*\*\*,  $p < 0.001$ , error bars = SEM,

515  $n=20$ .

516 (B) *tir-1(tm3036)* suppresses *egl-30(tg26)*. *egl-30(tg26) tir-1* animals move more slowly

517 than the hyperactive *egl-30(tg26)* animals. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n=20$ .

518 (C) *nsy-1(ok593)* mutant animals have slow locomotion. \*\*\*,  $p < 0.001$ , error bars = SEM,

519  $n=20$ .



520 (D) *nsy-1(ok593)* suppresses *egl-30(tg26)*. *egl-30(tg26) nsy-1* animals move more  
521 slowly than the hyperactive *egl-30(tg26)* animals. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n=20$ .  
522 (E) *pmk-2*, *pmk-2 pmk-1*, and *pmk-3* mutant animals have slow locomotion. \*\*\*,  $p <$   
523  $0.001$ ; \*,  $p < 0.05$ , compared to WT. Error bars = SEM,  $n=20$ .  
524 (F) A *pmk-2 pmk-1* double mutant suppresses the hyperactivity of *egl-30(tg26)*. \*\*\*,  $p <$   
525  $0.001$  compared to *egl-30(tg26)*. Error bars = SEM,  $n=20$ .  
526 (G, H) *tir-1(tm3036)*, *nsy-1(ok593)*, and the *pmk-2 pmk-1* double mutant suppress the  
527 loopy waveform of *egl-30(tg26)*. *egl-30(tg26)* animals with mutations in either *pmk-1*,  
528 *pmk-2*, or *pmk-3* are still loopy. (G) Worm photos. (H) Quantification. \*\*\*,  $p < 0.001$   
529 compared to *egl-30(tg26)*. Error bars = SEM,  $n=5$ .

530

#### 531 **Figure 4. *sek-1* acts in the same genetic pathway as *unc-73***

532 (A) *sek-1* does not act in the same genetic pathway as *egl-8*. The *sek-1(yak42)*  
533 mutation enhances the slow locomotion of the *egl-8(sa47)* mutant. \*\*\*,  $p < 0.001$ , error  
534 bars = SEM,  $n=20$ .

535 (B) *sek-1* does not act in the same genetic pathway as *rund-1*. The *sek-1(yak42)*  
536 mutation enhances the slow locomotion of the *rund-1(tm3622)* mutant. \*\*\*,  $p < 0.001$ ,  
537 error bars = SEM,  $n=20$ .

538 (C) *sek-1* may act in the same genetic pathway as *unc-73*. The *sek-1(yak42)* mutation  
539 does not enhance the slow locomotion phenotype of the *unc-73(ox317)* mutant. ns,  
540  $p > 0.05$ , error bars = SEM,  $n=20$ .

541 (D-E) *sek-1(km4)* does not suppress the loopy waveform of *nzls29 rho-1(gf)* animals.

542 (D) Worm photos. (E) Quantification. ns,  $p > 0.05$ , error bars = SEM,  $n=5$ .

543 (F) *sek-1(km4)* does not suppress the slow locomotion of *rho-1(gf)* animals. \*\*\*,  $p <$   
544 0.001, error bars = SEM,  $n=20$ .

545

546 **Figure 5. *sek-1* and *nsy-1* weakly suppress *nca-1(gf)***

547 (A) *nca-1(gf)* mutants are small, loopy, and uncoordinated. The phenotypes of *nca-*  
548 *1(ox352)* animals are partially suppressed by *sek-1(km4)* and *nsy-1(ok593)*. Photos of  
549 first-day adults.

550 (B) *sek-1(km4)* and *nsy-1(ok593)* suppress the loopy waveform of *nca-1(gf)*. \*\*\*,  
551  $p < 0.001$ ; \*\*,  $p < 0.01$ . Error bars = SEM,  $n=5$ .

552 (C) *sek-1* and *nsy-1* suppress *nca-1(gf)* locomotion. *nca-1(gf)* animals travel a small  
553 distance from the center of the plate in the radial locomotion assay. *nca-1(gf) nsy-*  
554 *1(ok593)* and *nca-1(gf) sek-1(km4)* worms move further than *nca-1(gf)* worms. \*\*,  
555  $p < 0.01$ ; \*,  $p < 0.05$ . Error bars = SEM,  $n=30$ .

556 (D) *sek-1* acts in acetylcholine neurons to modulate the size and loopy waveform of  
557 *nca-1(gf)*. *nca-1(ox352) sek-1(km4)* animals expressing *sek-1* in all neurons (*unc-*  
558 *119p::sek-1(+)*) or in acetylcholine neurons (*unc-17p::sek-1(+)*) are loopy and small like  
559 *nca-1(gf)*, but *nca-1(ox352) sek-1(km4)* animals expressing *sek-1* in GABA neurons  
560 (*unc-47p::sek-1(+)*) resemble *nca-1(gf) sek-1*. White arrowheads depict food piles  
561 created by *nca-1(gf) sek-1(km4)* animals due to their uncoordinated locomotion. Such  
562 food piles are not made by *nca-1(gf)* animals.

563 (E) *sek-1* acts in acetylcholine motoneurons to modulate the loopy waveform of *nca-*  
564 *1(gf)*. *nca-1(ox352) sek-1(km4)* worms expressing *sek-1* in all neurons (*unc-119p::sek-*  
565 *1(+)*), acetylcholine neurons (*unc-17p::sek-1(+)*), or acetylcholine motoneurons (*unc-*

566 *17βp::sek-1(+)* are loopy like *nca-1(gf)*, but *nca-1(ox352) sek-1(km4)* worms expressing  
567 *sek-1* in GABA neurons (*unc-47p::sek-1(+)*) or head acetylcholine neurons (*unc-*  
568 *17Hp::sek-1(+)*) are similar to *nca-1(gf) sek-1*. \*\*\*,  $p < 0.001$ , \*\*,  $p < 0.01$ ; ns,  $p > 0.05$ .  
569 Error bars = SEM,  $n=5$ .

570

## 571 **References**

572 Afgan, E., D. Baker, M. van den Beek, D. Blankenberg, D. Bouvier *et al.*, 2016 The  
573 Galaxy platform for accessible, reproducible and collaborative biomedical  
574 analyses: 2016 update. *Nucleic Acids Res.* 44: W3–W10.

575 Ailion, M., M. Hannemann, S. Dalton, A. Pappas, S. Watanabe *et al.*, 2014 Two Rab2  
576 interactors regulate dense-core vesicle maturation. *Neuron* 82: 167–180.

577 Andrusiak, M. G., and Y. Jin, 2016 Context Specificity of Stress-activated Mitogen-  
578 activated Protein (MAP) Kinase Signaling: The Story as Told by *Caenorhabditis*  
579 *elegans*. *J. Biol. Chem.* 291: 7796–7804.

580 Bastiani, C. A., S. Gharib, M. I. Simon, and P. W. Sternberg, 2003 *Caenorhabditis*  
581 *elegans* Gαq Regulates Egg-Laying Behavior via a PLCβ-Independent and  
582 Serotonin-Dependent Signaling Pathway and Likely Functions Both in the  
583 Nervous System and in Muscle. *Genetics* 165: 1805–1822.

584 Bence, K., W. Ma, T. Kozasa, and X.-Y. Huang, 1997 Direct stimulation of Bruton's  
585 tyrosine kinase by Gq-protein α-subunit. *Nature* 389: 296–299.

- 586 Bolshakov, V. Y., L. Carboni, M. H. Cobb, S. A. Siegelbaum, and F. Belardetti, 2000  
587 Dual MAP kinase pathways mediate opposing forms of long-term plasticity at  
588 CA3-CA1 synapses. *Nat. Neurosci.* 3: 1107–1112.
- 589 Brenner, S., 1974 The genetics of *Caenorhabditis elegans*. *Genetics* 77: 71–94.
- 590 Chang, C., Y.-W. Hsieh, B. J. Lesch, C. I. Bargmann, and C.-F. Chuang, 2011  
591 Microtubule-based localization of a synaptic calcium-signaling complex is  
592 required for left-right neuronal asymmetry in *C. elegans*. *Development* 138:  
593 3509–3518.
- 594 Chuang, C.-F., and C. I. Bargmann, 2005 A Toll-interleukin 1 repeat protein at the  
595 synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK  
596 signaling. *Genes Dev.* 19: 270–281.
- 597 Cingolani, P., A. Platts, L. L. Wang, M. Coon, T. Nguyen *et al.*, 2012 A program for  
598 annotating and predicting the effects of single nucleotide polymorphisms, SnpEff:  
599 SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly*  
600 6: 80–92.
- 601 Couillault, C., N. Pujol, J. Reboul, L. Sabatier, J.-F. Guichou *et al.*, 2004 TLR-  
602 independent control of innate immunity in *Caenorhabditis elegans* by the TIR  
603 domain adaptor protein TIR-1, an ortholog of human SARM. *Nat. Immunol.* 5:  
604 488–494.

- 605 DePristo, M. A., E. Banks, R. Poplin, K. V. Garimella, J. R. Maguire *et al.*, 2011 A  
606 framework for variation discovery and genotyping using next-generation DNA  
607 sequencing data. *Nat. Genet.* 43: 491–498.
- 608 Doi, M., and K. Iwasaki, 2002 Regulation of retrograde signaling at neuromuscular  
609 junctions by the novel C2 domain protein AEX-1. *Neuron* 33: 249–259.
- 610 Fay, D., 2006 Genetic mapping and manipulation: Chapter 7-Making compound  
611 mutants. *WormBook*, ed. The *C. elegans* Research Community, WormBook,  
612 doi/10.1895/wormbook.1.96.2, <http://www.wormbook.org>
- 613 Frøkjær-Jensen, C., M. W. Davis, M. Ailion, and E. M. Jorgensen, 2012 Improved  
614 Mos1-mediated transgenesis in *C. elegans*. *Nat. Methods* 9: 117–118.
- 615 Frøkjær-Jensen, C., M. W. Davis, M. Sarov, J. Taylor, S. Flibotte *et al.*, 2014 Random  
616 and targeted transgene insertion in *C. elegans* using a modified Mos1 transposon.  
617 *Nat. Methods* 11: 529–534.
- 618 Gao, S., L. Xie, T. Kawano, M. D. Po, J. K. Pirri *et al.*, 2015 The NCA sodium leak  
619 channel is required for persistent motor circuit activity that sustains locomotion.  
620 *Nat. Commun.* 6: 6323.
- 621 García-Hoz, C., G. Sánchez-Fernández, M. T. Díaz-Meco, J. Moscat, F. Mayor *et al.*,  
622 2010 Gαq Acts as an Adaptor Protein in Protein Kinase Cζ (PKCζ)-mediated  
623 ERK5 Activation by G Protein-coupled Receptors (GPCR). *J. Biol. Chem.* 285:  
624 13480–13489.

- 625 Hajdu-Cronin, Y. M., W. J. Chen, G. Patikoglou, M. R. Koelle, and P. W. Sternberg,  
626 1999 Antagonism between  $G\alpha$  and  $Gq\alpha$  in *Caenorhabditis elegans*: the RGS  
627 protein EAT-16 is necessary for  $G\alpha$  signaling and regulates  $Gq\alpha$  activity. *Genes*  
628 *Dev.* 13: 1780–1793.
- 629 Hawasli, A. H., O. Saifee, C. Liu, M. L. Nonet, and C. M. Crowder, 2004 Resistance to  
630 volatile anesthetics by mutations enhancing excitatory neurotransmitter release  
631 in *Caenorhabditis elegans*. *Genetics* 168: 831–843.
- 632 Hoppe, P. E., J. Chau, K. A. Flanagan, A. R. Reedy, and L. A. Schriefer, 2010  
633 *Caenorhabditis elegans* unc-82 Encodes a Serine/Threonine Kinase Important  
634 for Myosin Filament Organization in Muscle During Growth. *Genetics* 184: 79–90.
- 635 Huang, C.-C., J.-L. You, M.-Y. Wu, and K.-S. Hsu, 2004 Rap1-induced p38 mitogen-  
636 activated protein kinase activation facilitates AMPA receptor trafficking via the  
637 GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycine-induced  
638 long term depression. *J. Biol. Chem.* 279: 12286–12292.
- 639 Hudmon, A., J.-S. Choi, L. Tyrrell, J. A. Black, A. M. Rush *et al.*, 2008 Phosphorylation  
640 of Sodium Channel Nav1.8 by p38 Mitogen-Activated Protein Kinase Increases  
641 Current Density in Dorsal Root Ganglion Neurons. *J. Neurosci.* 28: 3190–3201.
- 642 Jantsch-Plunger, V., P. Gönczy, A. Romano, H. Schnabel, D. Hamill *et al.*, 2000 CYK-4:  
643 A Rho family gtpase activating protein (GAP) required for central spindle  
644 formation and cytokinesis. *J. Cell Biol.* 149: 1391–1404.

- 645 Kawasaki, M., 1999 A *Caenorhabditis elegans* JNK signal transduction pathway  
646 regulates coordinated movement via type-D GABAergic motor neurons. *EMBO J.*  
647 18: 3604–3615.
- 648 Kim, D. H., R. Feinbaum, G. Alloing, F. E. Emerson, D. A. Garsin *et al.*, 2002 A  
649 Conserved p38 MAP Kinase Pathway in *Caenorhabditis elegans* Innate  
650 Immunity. *Science* 297: 623–626.
- 651 Kim, D. H., N. T. Liberati, T. Mizuno, H. Inoue, N. Hisamoto *et al.*, 2004 Integration of  
652 *Caenorhabditis elegans* MAPK pathways mediating immunity and stress  
653 resistance by MEK-1 MAPK kinase and VHP-1 MAPK phosphatase. *Proc. Natl.*  
654 *Acad. Sci. U. S. A.* 101: 10990–10994.
- 655 Koelle, M. R., 2016 Neurotransmitter signaling through heterotrimeric G proteins:  
656 insights from studies in *C. elegans*. *WormBook*, doi:10.1895/wormbook.1.75.2.
- 657 Kyriakis, J. M., and J. Avruch, 2012 Mammalian MAPK signal transduction pathways  
658 activated by stress and inflammation: a 10-year update. *Physiol. Rev.* 92: 689–  
659 737.
- 660 Lackner, M. R., S. J. Nurrish, and J. M. Kaplan, 1999 Facilitation of synaptic  
661 transmission by EGL-30 Gqalpha and EGL-8 PLCbeta: DAG binding to UNC-13  
662 is required to stimulate acetylcholine release. *Neuron* 24: 335–346.
- 663 Lu, B., Y. Su, S. Das, J. Liu, J. Xia *et al.*, 2007 The Neuronal Channel NALCN  
664 Contributes Resting Sodium Permeability and Is Required for Normal Respiratory  
665 Rhythm. *Cell* 129: 371–383.

- 666 McMullan, R., E. Hiley, P. Morrison, and S. J. Nurrish, 2006 Rho is a presynaptic  
667 activator of neurotransmitter release at pre-existing synapses in *C. elegans*.  
668 *Genes Dev.* 20: 65–76.
- 669 Mello, C. C., J. M. Kramer, D. Stinchcomb, and V. Ambros, 1991 Efficient gene transfer  
670 in *C. elegans*: extrachromosomal maintenance and integration of transforming  
671 sequences. *EMBO J.* 10: 3959–3970.
- 672 Miller, K. G., M. D. Emerson, and J. B. Rand, 1999 Gqalpha and diacylglycerol kinase  
673 negatively regulate the Gqalpha pathway in *C. elegans*. *Neuron* 24: 323–333.
- 674 Nash, H. A., R. L. Scott, B. C. Lear, and R. Allada, 2002 An unusual cation channel  
675 mediates photic control of locomotion in *Drosophila*. *Curr. Biol.* 12: 2152–2158.
- 676 Natochin, M., and N. O. Artemyev, 2003 A point mutation uncouples transducin-alpha  
677 from the photoreceptor RGS and effector proteins. *J. Neurochem.* 87: 1262–  
678 1271.
- 679 Nurrish, S., L. Ségalat, and J. M. Kaplan, 1999 Serotonin inhibition of synaptic  
680 transmission: Galpha(0) decreases the abundance of UNC-13 at release sites.  
681 *Neuron* 24: 231–242.
- 682 Pagano, D. J., E. R. Kingston, and D. H. Kim, 2015 Tissue Expression Pattern of PMK-2  
683 p38 MAPK Is Established by the miR-58 Family in *C. elegans*. *PLoS Genet* 11:  
684 e1004997.




- 685 Park, E. C., and C. Rongo, 2016 The p38 MAP kinase pathway modulates the hypoxia  
686 response and glutamate receptor trafficking in aging neurons. *eLife* 5: e12010.
- 687 Plowman, G. D., S. Sudarsanam, J. Bingham, D. Whyte, and T. Hunter, 1999 The  
688 protein kinases of *Caenorhabditis elegans*: a model for signal transduction in  
689 multicellular organisms. *Proc. Natl. Acad. Sci. U. S. A.* 96: 13603–13610.
- 690 Rhee, S. G., 2001 Regulation of Phosphoinositide-Specific Phospholipase C. *Annu.*  
691 *Rev. Biochem.* 70: 281–312.
- 692 Rush, A. M., J. Wu, M. J. Rowan, and R. Anwyl, 2002 Group I metabotropic glutamate  
693 receptor (mGluR)-dependent long-term depression mediated via p38 mitogen-  
694 activated protein kinase is inhibited by previous high-frequency stimulation and  
695 activation of mGluRs and protein kinase C in the rat dentate gyrus in vitro. *J.*  
696 *Neurosci.* 22: 6121–6128.
- 697 Sagasti, A., N. Hisamoto, J. Hyodo, M. Tanaka-Hino, K. Matsumoto *et al.*, 2001 The  
698 CaMKII UNC-43 Activates the MAPKKK NSY-1 to Execute a Lateral Signaling  
699 Decision Required for Asymmetric Olfactory Neuron Fates. *Cell* 105: 221–232.
- 700 Sánchez-Fernández, G., S. Cabezudo, C. García-Hoz, C. Benincá, A. M. Aragay *et al.*,  
701 2014 Gαq signalling: The new and the old. *Cell. Signal.* 26: 833–848.
- 702 Shi, Y., C. Abe, B. B. Holloway, S. Shu, N. N. Kumar *et al.*, 2016 Nalcn Is a “Leak”  
703 Sodium Channel That Regulates Excitability of Brainstem Chemosensory  
704 Neurons and Breathing. *J. Neurosci.* 36: 8174–8187.


- 705 Shivers, R. P., T. Kooistra, S. W. Chu, D. J. Pagano, and D. H. Kim, 2009 Tissue-  
706 specific activities of an immune signaling module regulate physiological  
707 responses to pathogenic and nutritional bacteria in *C. elegans*. *Cell Host Microbe*  
708 6: 321–330.
- 709 Shivers, R. P., D. J. Pagano, T. Kooistra, C. E. Richardson, K. C. Reddy *et al.*, 2010  
710 Phosphorylation of the conserved transcription factor ATF-7 by PMK-1 p38  
711 MAPK regulates innate immunity in *Caenorhabditis elegans*. *PLoS Genet.* 6:  
712 e1000892.
- 713 Tanaka-Hino, M., A. Sagasti, N. Hisamoto, M. Kawasaki, S. Nakano *et al.*, 2002 SEK-1  
714 MAPKK mediates Ca<sup>2+</sup> signaling to determine neuronal asymmetric  
715 development in *Caenorhabditis elegans*. *EMBO Rep.* 3: 56–62.
- 716 Topalidou, I., J. Cattin-Ortolá, A. L. Pappas, K. Cooper, G. E. Merrihew *et al.*, 2016 The  
717 EARP Complex and Its Interactor EIPR-1 Are Required for Cargo Sorting to  
718 Dense-Core Vesicles. *PLOS Genet* 12: e1006074.
- 719 Topalidou, I., P.-A. Chen, K. Cooper, S. Watanabe, E. M. Jorgensen *et al.*, 2017 The  
720 NCA-1 and NCA-2 Ion Channels Function Downstream of Gq and Rho To  
721 Regulate Locomotion in *Caenorhabditis elegans*. *Genetics* 206: 265–282.
- 722 Vaqué, J. P., R. T. Dorsam, X. Feng, R. Iglesias-Bartolome, D. J. Forsthoefel *et al.*,  
723 2013 A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry  
724 transducing mitogenic signals initiated by G protein-coupled receptors. *Mol. Cell*  
725 49: 94–108.

- 726 Vashlishan, A. B., J. M. Madison, M. Dybbs, J. Bai, D. Sieburth *et al.*, 2008 An RNAi  
727 Screen Identifies Genes that Regulate GABA Synapses. *Neuron* 58: 346–361.
- 728 Williams, S. L., S. Lutz, N. K. Charlie, C. Vettel, M. Ailion *et al.*, 2007 Trio's Rho-specific  
729 GEF domain is the missing Galpha q effector in *C. elegans*. *Genes Dev.* 21:  
730 2731–2746.
- 731 Wittmack, E. K., A. M. Rush, A. Hudmon, S. G. Waxman, and S. D. Dib-Hajj, 2005  
732 Voltage-Gated Sodium Channel Nav1.6 Is Modulated by p38 Mitogen-Activated  
733 Protein Kinase. *J. Neurosci.* 25: 6621–6630.
- 734 Zhang, R., X. He, W. Liu, M. Lu, J.-T. Hsieh *et al.*, 2003 AIP1 mediates TNF- $\alpha$ -induced  
735 ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. *J.*  
736 *Clin. Invest.* 111: 1933–1943.
- 737


# Figure 4




## Figure 2




# Figure 3



## Figure 4



## Figure 5





## Supplementary Information

**Table S1. Strain List**

Strain	Genotype
AU1	<i>sek-1(ag1)</i> X
BS3383	<i>pmk-3(ok169)</i> IV
CX3695	<i>kyls140[<i>str-2p::gfp</i>, <i>lin-15(+)</i>]</i> I
CX5959	<i>kyls140[<i>str-2p::gfp</i>, <i>lin-15(+)</i>]</i> I; <i>tir-1(ky648gf)</i> III
EG317	<i>unc-73(ox317)</i> I
EG1000	<i>dpy-5(e61)</i> I; <i>rol-6(e187)</i> II; <i>lon-1(e1820)</i> III
EG1020	<i>bli-6(sc16)</i> IV; <i>dpy-11(e224)</i> V; <i>lon-2(e678)</i> X
EG3745	<i>eat-16(tm775)</i> I ; <i>him-5(e1490)</i> V
EG4782	<i>nzls29[<i>unc-17p::rho-1(G14V)</i>, <i>unc-122::gfp</i>]</i> II
EG5505	<i>rund-1(tm3622)</i> X
EG7989	<i>unc-119(ed3)</i> III; <i>oxTi668[<i>eft-3p::TdTomato::H2B</i>, <i>Cb-unc-119(+)</i>]</i> X
IG685	<i>tir-1(tm3036)</i> III
JN147	<i>gap-2(tm748)</i> X
JT47	<i>egl-8(sa47)</i> V
JT366	<i>vhp-1(sa366)</i> II
JT734	<i>goa-1(sa734)</i> I
KU2	<i>jkk-1(km2)</i> X
KU4	<i>sek-1(km4)</i> X
KU25	<i>pmk-1(km25)</i> IV
N2	Bristol wild isolate, standard lab wild-type
NM1380	<i>egl-30(js126gf)</i> I

VC8	<i>jnk-1(gk7)</i> IV
VC390	<i>nsy-1(ok593)</i> IV
XZ42	<i>sek-1(yak42)</i> X
XZ1233	<i>egl-30(tg26)</i> I; <i>sek-1(yak42)</i> X
XZ1151	<i>egl-30(tg26)</i> I
XZ1566	<i>egl-8(sa47)</i> V; <i>sek-1(yak42)</i> X
XZ1567	<i>unc-73(ox317)</i> I; <i>sek-1(yak42)</i> X
XZ1574	<i>rund-1(tm3622)</i> <i>sek-1(yak42)</i> X
XZ1575	<i>egl-30(tg26)</i> I; <i>sek-1(km4)</i> X
XZ1588	<i>egl-30(tg26)</i> I; <i>nsy-1(ok593)</i> IV
XZ1589	<i>egl-30(tg26)</i> I; <i>sek-1(km4)</i> X; <i>qdEx8[unc-119p::sek-1::GFP, myo-2p::mStrawberry::unc-54-3'UTR]</i>
XZ1590	<i>egl-30(tg26)</i> I ; <i>jkk-1(km2)</i> X
XZ1593	<i>egl-30(tg26)</i> I; <i>pmk-1(km25)</i> IV
XZ1597	<i>egl-30(tg26)</i> I ; <i>jnk-1(gk7)</i> IV
XZ1642	<i>sek-1(km4)</i> X; <i>yakEx72[unc-17p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1643	<i>sek-1(km4)</i> X; <i>yakEx73[unc-47p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1717	<i>nzls29[unc-17p::rho-1(G14V) unc-122::gfp]</i> II; <i>sek-1(km4)</i> X
XZ1720	<i>sek-1(km4)</i> X ; <i>yakEx82[unc-17Hp::sek-1:: tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1721	<i>sek-1(km4)</i> X ; <i>yakEx83[unc-17βp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1770	<i>egl-30(tg26)</i> I; <i>pmk-2(qd279 qd171)</i> <i>pmk-1(km25)</i> IV

XZ1771	<i>egl-30(tg26) I; pmk-2(qd287) IV</i>
XZ1772	<i>egl-30(tg26) I; pmk-3(ok169) IV</i>
XZ1815	<i>egl-30(tg26) I; tir-1(tm3036) III</i>
XZ1816	<i>nca-1(ox352) IV; sek-1(km4) X; qdEx8[unc-119p::sek-1::GFP::unc-54-3' UTR, myo-2p::mStrawberry::unc-54-3'UTR]</i>
XZ1820	<i>nca-1(ox352) IV ; sek-1(km4) X ; yakEx83[unc-17βp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1830	<i>egl-30(tg26) I ; sek-1(km4) X ; yakEx83[unc-17βp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1834	<i>egl-30(tg26) I; sek-1(km4) X; yakEx72[unc-17p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1835	<i>nca-1(ox352) IV; sek-1(km4) X; yakEx72[unc-17p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1861	<i>nca-1(ox352) IV; sek-1(km4) X; yakEx73[unc-47p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1862	<i>nca-1(ox352) IV ; sek-1(km4) X ; yakEx82[unc-17Hp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1863	<i>egl-30(tg26) I; sek-1(km4) X; yakEx73[unc-47p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1872	<i>jnk-1(gk7) I; sek-1(km4) X</i>
XZ1873	<i>pmk-2(qd279 qd171) pmk-1(km25) IV; jkk-1(km2) X</i>
XZ1879	<i>egl-30(tg26) I ; sek-1(km4) X ; yakEx82[unc-17Hp:: sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr, myo-2p::mCherry]</i>
XZ1902	<i>egl-30(tg26) I ; unc-82(e1220) IV</i>
XZ1937	<i>sek-1(km4) X; yakEx121[hsp-16.2p::sek-1::tbb-2-3' UTR::gld-1 operon</i>

	<i>linker::gfp::h2b, myo-2p::mCherry]</i>
XZ1938	<i>egl-30(tg26) I ; agls219[T24B8.5p::GFP::unc-54-3'UTR + ttx-3p::GFP::unc-54-3'UTR] III attf-7(qd22 qd130) III</i>
XZ1939	<i>goa-1(sa734) I; sek-1(km4) X</i>
XZ1942	<i>tir-1(ky648gf) III</i>
XZ2054	<i>eat-16(tm775) I ; sek-1(km4) X</i>
XZ2062	<i>egl-30(js126gf) I ; sek-1(km4) X</i>
ZD202	<i>sek-1(km4) X; qdEx8[unc-119p::sek-1::GFP::unc-54-3' UTR + myo-2p::mStrawberry::unc-54-3'UTR]</i>
ZD318	<i>agls29 attf-7(qd22 qd130) III</i>
ZD442	<i>agls29 attf-7(qd22) III</i>
ZD934	<i>pmk-2(qd279 qd171) pmk-1(km25) IV</i>
ZD1020	<i>pmk-2(qd287) IV</i>

## Table S2. Plasmids and Primers

### Gateway entry clones

Plasmid	Details
pADA180	<i>unc-17Hp</i> [4-1]
pJH21	<i>sek-1</i> cDNA [1-2]
pCFJ150	pDEST5605[4-3]
pCFJ326	<i>tbb-2utr-operon-GFP::H2B::cye-1utr</i> [2-3]
pMA23	<i>unc-17βp</i> [4-1]
pMH522	<i>unc-47p</i> [4-1]
pGH1	<i>unc-17p</i> [4-1]
pCM1.56	<i>hsp-16.2p</i> [4-1]

## Gateway Expression Constructs

Plasmid	Details	Used to make
pJH23	<i>unc-17p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr</i>	<i>yakEx72</i>
pJH24	<i>unc-47p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr</i>	<i>yakEx73</i>
pJH28	<i>unc-17Hp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr</i>	<i>yakEx82</i>
pJH29	<i>unc-17βp::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr</i>	<i>yakEx83</i>
pJH46	<i>hsp-16.2p::sek-1::tbb-2utr-operon-GFP::H2B::cye-1utr</i>	<i>yakEx121</i>

## Primers

oJH114	GGGGACAAGTTTGTACAAAAAAGCA GGCTcaATGGAGCGAAAAGGACGT G	F to clone <i>sek-1</i> cDNA into [1-2]
oJH115	GGGGACCACTTTGTACAAGAAAGCT GGGTgTCATCGTCGCCAAACAGTG	R to clone <i>sek-1</i> cDNA into [1-2]

## Table S3. Statistical Tests

Figure	Test	p value
1C	One-way ANOVA and Bonferroni's Multiple Comparison Test WT vs <i>sek-1(km4)</i> (ns)	< 0.001

	<p>WT vs <i>egl-30(tg26)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(km4)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(yak42)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); unc-82(e1220)</i> (ns)</p>	
1E	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(yak42)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(km4)</i> (p&lt;0.001)</p>	< 0.001
1F	<p>One-way ANOVA and Dunnett's Multiple Comparison Test</p> <p>WT vs <i>sek-1(yak42)</i> (p&lt;0.001)</p> <p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p>	< 0.001
1G	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(js126)</i> (p&lt;0.001)</p> <p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p><i>egl-30(js126)</i> vs <i>egl-30(js126); sek-1(km4)</i> (p&lt;0.001)</p>	< 0.001
1H	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(js126)</i> (p&lt;0.001)</p> <p><i>egl-30(js126)</i> vs <i>egl-30(js126); sek-1(km4)</i> (p&lt;0.001)</p>	<0.001
2A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); qdEx8[unc-119::sek-1(+)]</i> (p&lt;0.001)</p>	< 0.001
2B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p>	<0.001
2D	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (p&lt;0.001)</p>	<0.001

	<p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); qdEx8[unc-119p::sek-1(+)]</i>                  (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i>                  (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p>	
2E	<p>Kruskal-Wallis Test and Dunn's Multiple Comparison Test</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); qdEx8[unc-119p::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i> (p&lt;0.01)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs  <i>egl-30(tg26); sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p>	< 0.001
2F	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); yakEx121[hsp-16.2p::sek-1(+)]</i>                  (p&lt;0.001)</p>	< 0.001
3A	<p>Unpaired t test, two-tailed</p>	< 0.001
3B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); tir-1(tm3036)</i> (p&lt;0.001)</p>	< 0.001
3C	<p>Unpaired t test, two-tailed</p>	< 0.001
3D	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); nsy-1(ok593)</i> (p&lt;0.001)</p>	< 0.001
3E	<p>One-way ANOVA and Dunnett's Multiple Comparison Test</p>	< 0.001

	<p>WT vs <i>pmk-1(km25)</i> (ns)</p> <p>WT vs <i>pmk-2(qd287)</i> (<math>p &lt; 0.05</math>)</p> <p>WT vs <i>pmk-2(qd279 qd171) pmk-1 (km25)</i> (<math>p &lt; 0.001</math>)</p> <p>WT vs <i>pmk-3(ok169)</i> (<math>p &lt; 0.001</math>)</p>	
3F	<p>One-way ANOVA and Dunnett's Multiple Comparison Test</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); pmk-1(km25)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); pmk-2(qd287)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); pmk-2(qd279 qd171) pmk-1 (km25)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); pmk-3(ok169)</i> (<math>p &lt; 0.001</math>)</p>	< 0.001
3H	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); tir-1(tm3036)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); nsy-1(ok593)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(km4)</i> (<math>p &lt; 0.001</math>)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); pmk-2(qd279 qd171) pmk-1(km25)</i> (<math>p &lt; 0.001</math>)</p>	< 0.001
4A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>egl-8(sa47)</i> vs <i>egl-8(sa47); sek-1(yak42)</i> (<math>p &lt; 0.001</math>)</p>	< 0.001
4B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>sek-1(yak42)</i> vs <i>rund-1(tm3622); sek-1(yak42)</i> (<math>p &lt; 0.001</math>)</p>	< 0.001
4C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>unc-73(ox317)</i> vs <i>unc-73(ox317); sek-1(yak42)</i> (ns)</p>	< 0.001
4E	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>nzls29[unc-17p::rho-1(G14V)]</i> (<math>p &lt; 0.001</math>)</p> <p>WT vs <i>nzls29[unc-17p::rho-1(G14V)]; sek-1(km4)</i> (<math>p &lt; 0.001</math>)</p>	< 0.001



	<p><i>nzls29[unc-17p::rho-1(G14V)] vs</i></p> <p><i>nzls29[unc-17p::rho-1(G14V)]; sek-1(km4) (ns)</i></p>	
4F	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>nzls29[unc-17p::rho-1(G14V)] vs</i></p> <p><i>nzls29[unc-17p::rho-1(G14V)]; sek-1(km4) (p&lt;0.001)</i></p>	< 0.001
5B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>sek-1(km4) (ns)</i></p> <p>WT vs <i>nca-1(ox352) (p&lt;0.001)</i></p> <p><i>nca-1(ox352) vs nca-1(ox352); sek-1(km4) (p&lt;0.01)</i></p> <p><i>nca-1(ox352) vs nca-1(ox352); nsy-1(ok593) (p&lt;0.001)</i></p>	<0.001
5C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>nca-1(ox352) (p&lt;0.001)</i></p> <p><i>nca-1(ox352) vs nca-1(ox352); nsy-1(ok593) (p&lt;0.01)</i></p> <p><i>nca-1(ox352) vs nca-1(ox352); sek-1(km4) (p&lt;0.05)</i></p>	< 0.001
5E	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>nca-1(ox352) vs nca-1(ox352); sek-1(km4) (p&lt;0.001)</i></p> <p><i>nca-1(ox352); sek-1(km4) vs</i></p> <p><i>nca-1(ox352); sek-1(km4); qdEx8[unc-119p::sek-1(+)]</i></p> <p>(p&lt;0.001)</p> <p><i>nca-1(ox352); sek-1(km4) vs</i></p> <p><i>nca-1(ox352); sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i></p> <p>(p&lt;0.01)</p> <p><i>nca-1(ox352); sek-1(km4) vs</i></p> <p><i>nca-1(ox352); sek-1(km4); yakEx73[unc-47p::sek-1(+)] (ns)</i></p> <p><i>nca-1(ox352); sek-1(km4) vs</i></p>	< 0.001


	<p><i>nca-1(ox352); sek-1(km4); yakEx82[unc-17Hp::sek-1(+)]</i> (ns)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs</p> <p><i>nca-1(ox352); sek-1(km4); yakEx83[unc-17βp::sek-1(+)]</i></p> <p>(p&lt;0.001)</p>	
S1A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (p&lt;0.01)</p> <p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); sek-1(km4)</i> (p&lt;0.001)</p> <p><i>sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4)</i> (p&lt;0.01)</p>	< 0.001
S1B	<p>One-way ANOVA and Newman-Keuls Multiple Comparison Test</p> <p>WT vs <i>sek-1(yak42)</i> (p&lt;0.001)</p> <p>WT vs <i>sek-1(ag1)</i> (p&lt;0.001)</p> <p><i>sek-1(yak42)</i> vs <i>sek-1(ag1)</i> (ns)</p>	< 0.001
S1C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (ns)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); unc-82(e1220)</i> (p&lt;0.001)</p>	< 0.001
S1D	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p><i>goa-1(sa734)</i> vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p><i>goa-1(sa734)</i> vs <i>goa-1(sa734); sek-1(km4)</i> (p&lt;0.001)</p>	< 0.001
S1E	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>sek-1(km4)</i> (ns)</p> <p>WT vs <i>goa-1(sa734)</i> (p&lt;0.001)</p> <p><i>goa-1(sa734)</i> vs <i>goa-1(sa734); sek-1(km4)</i> (p&lt;0.001)</p>	< 0.001
S1F	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p>	< 0.001

	<p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p>WT vs <i>eat-16(tm775)</i> (p&lt;0.001)</p> <p><i>eat-16(tm775)</i> vs <i>eat-16(tm775); sek-1(km4)</i> (p&lt;0.001)</p> <p><i>sek-1(km4)</i> vs <i>eat-16(tm775); sek-1(km4)</i> (ns)</p>	
S1G	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>eat-16(tm775)</i> (p&lt;0.001)</p> <p><i>eat-16(tm775)</i> vs <i>eat-16(tm775); sek-1(km4)</i> (ns)</p>	< 0.001
S2A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>sek-1(km4)</i> (p&lt;0.001)</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); yakEx82[unc-17Hp::sek-1(+)]</i> (p&lt;0.05)</p> <p><i>sek-1(km4)</i> vs <i>sek-1(km4); yakEx83[unc-17βp::sek-1(+)]</i> (p&lt;0.01)</p>	< 0.001
S2B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); yakEx82[unc-17Hp::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); yakEx83[unc-17βp::sek-1(+)]</i> (p&lt;0.001)</p>	< 0.001
S2C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); qdEx8[unc-119p::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs</p>	< 0.001

	<p><i>egl-30(tg26); sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); yakEx82[unc-17Hp::sek-1(+)]</i> (p&lt;0.001)</p> <p><i>egl-30(tg26); sek-1(km4)</i> vs <i>egl-30(tg26); sek-1(km4); yakEx83[unc-17βp::sek-1(+)]</i> (ns)</p>	
S3A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>jnk-1(gk7)</i> vs <i>jnk-1(gk7); sek-1(km4)</i> (p&lt;0.01)</p> <p><i>jkk-1(km2)</i> vs <i>pmk-2(qd279 qd171) pmk-1 (km25); jkk-1(km2)</i> (p&lt;0.05)</p>	< 0.05
S3B	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>egl-30(tg26)</i> (P&lt;0.001)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); jkk-1</i> (ns)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); jnk-1</i> (ns)</p> <p><i>egl-30(tg26)</i> vs <i>egl-30(tg26); atf-7</i> (ns)</p>	
S3C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>atf-7(qd22)</i> (p&lt;0.001)</p> <p>WT vs <i>atf-7(qd22 qd130)</i> (p&lt;0.001)</p>	< 0.001
S3D	One-way ANOVA	p=0.806
S3F	Unpaired t test, two-tailed	< 0.001
S4A	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p>WT vs <i>nca-1(ox352)</i> (p&lt;0.001)</p> <p><i>nca-1(ox352)</i> vs <i>nca-1(ox352); sek-1(km4)</i> (p&lt;0.001)</p> <p><i>nca-1(ox352)</i> vs <i>nca-1(ox352); nsy-1(ok593)</i> (p&lt;0.001)</p>	<0.001
S4B	Kruskal-Wallis Test and Dunn's Multiple Comparison Test	0.001

	<p><i>nca-1(ox352);sek-1(km4)</i> vs <i>nca-1(ox352);sek-1(km4);</i>  <i>qdEx8[unc-119p::sek-1(+)]</i> (ns)</p> <p><i>nca-1(ox352);sek-1(km4)</i> vs  <i>nca-1(ox352);sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i> (ns)</p> <p><i>nca-1(ox352);sek-1(km4)</i> vs  <i>nca-1(ox352);sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p>	
S4C	<p>One-way ANOVA and Bonferroni's Multiple Comparison Test</p> <p><i>nca-1(ox352)</i> vs <i>nca-1(ox352); sek-1(km4)</i> (p&lt;0.001)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs  <i>nca-1(ox352); sek-1(km4); qdEx8[unc-119p::sek-1(+)]</i>          (p&lt;0.001)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs  <i>nca-1(ox352); sek-1(km4); yakEx72[unc-17p::sek-1(+)]</i>          (p&lt;0.001)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs  <i>nca-1(ox352); sek-1(km4); yakEx73[unc-47p::sek-1(+)]</i> (ns)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs  <i>nca-1(ox352); sek-1(km4); yakEx82[unc-17Hp::sek-1(+)]</i>          (p&lt;0.001)</p> <p><i>nca-1(ox352); sek-1(km4)</i> vs  <i>nca-1(ox352); sek-1(km4); yakEx83[unc-17βp::sek-1(+)]</i>          (p&lt;0.001)</p>	<0.001

## Figure S1



### Figure S1. *sek-1* interacts with Gq and Go mutants

(A) The *sek-1(km4)* mutation suppresses the hyperactive locomotion of the activated Gq mutant *egl-30(tg26)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .

(B) *sek-1(ag1)* mutant animals have slow locomotion. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 10$ .

(C) The *unc-82(e1220)* mutation reduces the locomotion rate of the activated Gq mutant *egl-30(tg26)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .


(D) *sek-1(km4)* suppresses the hyperactivity of *goa-1(sa734)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .

(E) *sek-1(km4)* suppresses the loopy waveform of *goa-1(sa734)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 5$ .

(F) *sek-1(km4)* suppresses the hyperactivity of *eat-16(tm775)*. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 20$ .

(G) *sek-1(km4)* does not suppress the loopy waveform of *eat-16(tm775)*. ns,  $p > 0.05$ , error bars = SEM,  $n = 5$ .

## Figure S2




### Figure S2. *sek-1* acts in both head acetylcholine neurons and acetylcholine motoneurons

(A) *sek-1* acts in acetylcholine motoneurons to modulate locomotion rate. The *sek-1* WT cDNA driven by the *unc-17β* acetylcholine motoneuron promoter [*unc-17βp::sek-1(+)*] rescues the slow locomotion phenotype of *sek-1(km4)* worms, but *sek-1* expression in head acetylcholine neurons using the *unc-17H* promoter [*unc-17Hp::sek-1(+)*] does not rescue. \*\*,  $p < 0.01$ ; \*,  $p < 0.05$  compared to *sek-1*. Error bars = SEM,  $n=20$ .

(B) *sek-1* acts in both head acetylcholine neurons and acetylcholine motoneurons to modulate the locomotion rate of the activated Gq mutant *egl-30(tg26)*. *egl-30(tg26) sek-1(km4)* worms expressing either *unc-17Hp::sek-1(+)* or *unc-17βp::sek-1(+)* have an increased locomotion rate compared to *egl-30(tg26) sek-1*. \*\*\*,  $p < 0.001$  compared to *egl-30(tg26) sek-1*. Error bars = SEM,  $n=20$ .

(C) *sek-1* acts in head acetylcholine neurons to modulate the loopy waveform of the activated Gq mutant *egl-30(tg26)*. *egl-30(tg26) sek-1(km4)* worms expressing *unc-17Hp::sek-1(+)* are loopy like *egl-30(tg26)*, but *egl-30(tg26) sek-1(km4)* worms expressing *unc-17βp::sek-1(+)* are similar to *egl-30(tg26) sek-1*. \*\*\*,  $p < 0.001$ ; ns,  $p > 0.05$  compared to *egl-30(tg26) sek-1*. Error bars = SEM,  $n=5$ .

## Figure S3



### Figure S3. Locomotion of p38 and JNK MAPK pathway mutants

(A) *jkk-1* and *jnk-1* act in parallel to *sek-1* and *pmk-2 pmk-1*. The *jnk-1(gk7) sek-1(km4)* double mutant and *pmk-2(qd279 qd171) pmk-1(km25) jkk-1(km2)* triple mutants move more slowly than the respective individual mutants. \*\*,  $p < 0.01$ , \*,  $p < 0.05$ . Error bars = SEM,  $n=20$ .

(B) Mutations in *jkk-1*, *jnk-1*, and *atf-7* do not suppress the loopy waveform of the activated Gq mutant *egl-30(tg26)*. ns,  $p > 0.05$ , error bars = SEM,  $n=5$ .


(C) Worms with gain-of-function or loss-of-function alleles of *atf-7* are slower than wild-type worms. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n=20$ .

(D) Worms lacking *gap-2* and *vhp-1* move like wild-type worms. Neither *gap-2(tm478)* nor *vhp-1(sa366)* confers a slow locomotion phenotype. ns,  $p > 0.05$  compared to WT. Error bars = SEM,  $n=20$ .

(E-F) *tir-1(ky648gf)* animals do not have loopy or hyperactive locomotion. *tir-1(ky648gf)* worms have wild-type posture and are slower than wild-type animals. \*\*\*,  $p < 0.001$ , error bars = SEM,  $n=20$ .



## Figure S4



### Figure S4. *sek-1* and *nsy-1* weakly suppress *nca-1(gf)*

(A) Mutations in *sek-1* and *nsy-1* suppress the small body size of *nca-1(ox352)* mutant worms.

\*\*\*,  $p < 0.001$ , error bars = SEM,  $n = 10$ .

(B) None of the neuronal *sek-1* rescuing constructs reverse the radial locomotion phenotype of *nca-1(gf) sek-1(km4)* animals. ns,  $p > 0.05$ . Error bars = SEM,  $n = 19-24$ .

(C) *sek-1* acts in both head acetylcholine neurons and acetylcholine motoneurons to control the body size of *nca-1(gf)*. *nca-1(ox352) sek-1(km4)* worms expressing *sek-1* in all neurons (*unc-119p::sek-1(+)*), acetylcholine neurons (*unc-17p::sek-1(+)*), head acetylcholine neurons (*unc-17Hp::sek-1(+)*), or acetylcholine motoneurons (*unc-17βp::sek-1(+)*) have a similar size to *nca-1(gf)*, but *nca-1(ox352) sek-1(km4)* worms expressing *sek-1* in GABA neurons (*unc-47p::sek-1(+)*) are similar to *nca-1(gf) sek-1*.

\*\*\*,  $p < 0.001$ ; ns,  $p > 0.05$ . Error bars = SEM,  $n = 7-10$ .